

# USE OF PALIVIZUMAB IN THE IMMUNOPROFILAXIS OF RESPIRATORY SYNCYTIAL VIRUS

Marín M, Alzueta N, Pío M, Gascón A.

Hospital Reina Sofía (Tudela). Servicio Navarro de Salud-Osasunbidea.

## BACKGROUND

Palivizumab is a monoclonal antibody that provides passive immunity against respiratory syncytial virus (RSV).

## PURPOSE

To evaluate the use of palivizumab as immunoprophylaxis against RSV in the 2016-2017 campaign in a tertiary hospital.

## MATERIAL AND METHODS

Retrospective observational study (October 2016-March 2017)  
Patients who received palivizumab as immunoprophylaxis against RSV



Prescription criteria established by *Spanish Society of Neonatology (SEN)*:

- A: Children <2 years with bronchopulmonary disease
- B: Children <2 years and congenital heart disease
- C: Gestational age <28 weeks and age <12 months
- D: Gestational age 29-32 weeks and age <6 months
- E: Gestational age 32-35 weeks and age <10 weeks and brother/sister of school age



Rapid Antigen-Based Testing for RSV was done


## RESULTS

20 patients  
Sex: 55% male  
Age: 6.8 (5.12) months  
Mean dose (SD): 93.10 (31.10) mg  
Mean administrations (SD): 2.1 (0.75)

1 patient (0.05%) was hospitalized  
Diagnostic: Bronchiolitis  
RSV test: +  
Palivizumab doses: 1

TOTAL COST:  
42,528.9 euros

### PRESCRIPTION CRITERIA ESTABLISHED BY SEN



## CONCLUSIONS

- ✓ Palivizumab has been effective in the prevention of RSV bronchiolitis in high-risk patients
- ✓ In all cases it has been used under the criteria established by the SEN. More studies are needed to assess the effectiveness with these criteria.
- ✓ According to the results obtained we shall proceed to the establishment of an action protocol for the next vaccination campaign in the hospital.